Article
Multidisciplinary Sciences
Aziza Kantri, Jihane Ziati, Mohamed Khalis, Amal Haoudar, Karim El Aidaoui, Youssef Daoudi, Inas Chikhaoui, Khalid El Yamani, Mohammed Mouhaoui, Jalila El Bakkouri, Nezha Dini, Mohammed Mahi, Abdelhamid Naitlho, Abdelkrim Bahlaoui, Ahmed Bennana, Mustapha Noussair, Lahcen Belyamani, Chafik El Kettani
Summary: This study critically analyzed the clinical and biological characteristics of 134 patients from the North African Mediterranean region with COVID-19, finding that factors such as age, comorbidities, gender, and infection type were associated with disease progression to a severe state. Abnormalities in certain parameters were closely linked to disease deterioration.
Article
Cardiac & Cardiovascular Systems
Thomas S. Metkus, Lori J. Sokoll, Andreas S. Barth, Matthew J. Czarny, Allison G. Hays, Charles J. Lowenstein, Erin D. Michos, Eric P. Nolley, Wendy S. Post, Jon R. Resar, David R. Thiemann, Jeffrey C. Trost, Rani K. Hasan
Summary: The study found that over 50% of intubated patients with severe COVID-19 had myocardial injury, which was associated with a higher mortality rate. Myocardial injury in COVID-19 was closely related to baseline comorbidities, age, and multisystem organ dysfunction. Compared with ARDS patients without COVID-19, COVID-19 patients were older and had poorer cardiac function, but had a lower incidence of myocardial injury.
Article
Virology
Enric Monreal, Sainz S. de la Maza, Pedro Gullon, Elena Natera-Villalba, Juan Luis Chico-Garcia, Alvaro Beltran-Corbellini, Javier Martinez-Sanz, Nuria Garcia-Barragan, Javier Buisan, Rafael Toledano, Araceli Alonso-Canovas, Paula Perez-Torre, Maria C. Matute-Lozano, Jose Luis Lopez-Sendon, Guillermo Garcia-Ribas, Inigo Corral, Jesus Fortun, Beatriz Montero-Errasquin, Luis Manzano, Luis Maiz-Carro, Lucienne Costa-Frossard, Jaime Masjuan
Summary: This study found that immunosuppression may reduce the risk of moderate to severe ARDS in COVID-19 patients, especially among those with autoimmune diseases.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Allergy
Yochai Adir, Marc Humbert, Walid Saliba
Summary: The study found that biologics approved for asthma and systemic corticosteroids do not increase the risk of SARS-CoV-2 infection. However, systemic corticosteroids are associated with worse COVID-19 severity and higher all-cause mortality.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Harpal Singh Sandhu, Joshua Lambert, Zach Steckler, Lee Park, Arnold Stromberg, Julio Ramirez, Chi-fu Jeffrey Yang
Summary: This study aimed to evaluate whether outpatient medications approved by the FDA reduce the risk of COVID-19 hospitalization. A retrospective cohort study of COVID-19 patients in the US in 2020 found that rosuvastatin, empagliflozin-metformin, metformin, and enoxaparin showed protective effects against COVID-19 hospitalization. Well-designed clinical trials are needed to assess the efficacy of these agents in therapeutic or prophylactic settings.
Article
Critical Care Medicine
Julien Lopinto, Romain Arrestier, Bastien Peiffer, Antoine Gaillet, Guillaume Voiriot, Tomas Urbina, Charles-Edouard Luyt, Raphael Bellaiche, Tai Pham, Zakaria Ait-Hamou, Damien Roux, Raphael Clere-Jehl, Elie Azoulay, Stephane Gaudry, Julien Mayaux, Armand Mekontso Dessap, Florence Canoui-Poitrine, Nicolas de Prost
Summary: High doses of corticosteroids (HDCT) in critically ill COVID-19 patients with nonresolving acute respiratory distress syndrome (ARDS) leads to an increased 90-day mortality.
CRITICAL CARE MEDICINE
(2023)
Article
Infectious Diseases
Enric Monreal, Susana Sainz de la Maza, Elena Natera-Villalba, Alvaro Beltran-Corbellini, Fernando Rodriguez-Jorge, Jose Ignacio Fernandez-Velasco, Paulette Walo-Delgado, Alfonso Muriel, Javier Zamora, Araceli Alonso-Canovas, Jesus Fortun, Luis Manzano, Beatriz Montero-Errasquin, Lucienne Costa-Frossard, Jaime Masjuan, Luisa Maria Villar
Summary: Using high doses of corticosteroids in severe COVID-19 patients is associated with higher mortality and increased risk of needing mechanical ventilation or death, particularly in elderly patients. However, the risk of developing severe ARDS is similar between high and standard doses of corticosteroids.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Julia Diaz-Escobar, Nelson E. Ordonez-Guillen, Salvador Villarreal-Reyes, Alejandro Galaviz-Mosqueda, Vitaly Kober, Raul Rivera-Rodriguez, Jose E. Lozano Rizk
Summary: The study evaluates and compares deep-learning techniques for detecting COVID-19 infections from lung ultrasound imagery. The findings suggest that the InceptionV3 network provides the most promising predictive results, which can be used to further develop a viable computer-assisted screening tool for COVID-19 based on ultrasound imagery.
Article
Medicine, General & Internal
Michele Umbrello, Paolo Formenti, Stefano Nespoli, Eleonora Pisano, Cecilia Bonino, Stefano Muttini
Summary: Systemic corticosteroids, including dexamethasone and methylprednisolone, showed no significant difference in outcomes such as ICU stay duration, hospital mortality, and infectious complications. However, emergency, short-term, high-dose corticosteroid boluses were generally associated with worse outcomes. A subgroup of subjects receiving the boluses did show improved oxygenation and lower hospital mortality.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Microbiology
Jessica A. Plante, Brooke M. Mitchell, Kenneth S. Plante, Kari Debbink, Scott C. Weaver, Vineet D. Menachery
Summary: Despite the development of vaccines, COVID-19 caused by SARS-CoV-2 continues to be a global concern due to the emergence of new variants, raising worries about increased spread and potential impacts on immunity.
CELL HOST & MICROBE
(2021)
Article
Biochemistry & Molecular Biology
Atsuko Deguchi, Tomoko Yamamoto, Noriyuki Shibata, Yoshiro Maru
Summary: This study investigates the potential role of S100A8 in COVID-19-associated ARDS and proposes a treatment method. Pathological similarities, clinical information, and experimental results collectively support the importance of S100A8 in COVID-19.
Review
Pediatrics
Reza Sinaei, Sara Pezeshki, Saeedeh Parvaresh, Roya Sinaei
Summary: Research suggests that children are less frequently and severely affected by SARS-CoV-2 infection compared to adults, potentially due to factors such as a healthier respiratory system, less vigorous immune response, and other immune characteristics.
WORLD JOURNAL OF PEDIATRICS
(2021)
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran, Evan C. Lam, Michael G. Astudillo, Diane Yang, Tyler E. Miller, Jared Feldman, Blake M. Hauser, Timothy M. Caradonna, Kiera L. Clayton, Adam D. Nitido, Mandakolathur R. Murali, Galit Alter, Richelle C. Charles, Anand Dighe, John A. Branda, Jochen K. Lennerz, Daniel Lingwood, Aaron G. Schmidt, A. John Iafrate, Alejandro B. Balazs
Summary: Severe cases of COVID-19 show increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high antibody levels. High neutralization potency is a predictor of survival. Patient sera can neutralize different strains, indicating cross-protection from reinfection.
Article
Multidisciplinary Sciences
Jun Wu, Boyun Liang, Cunrong Chen, Hua Wang, Yaohui Fang, Shu Shen, Xiaoli Yang, Baoju Wang, Liangkai Chen, Qi Chen, Yang Wu, Jia Liu, Xuecheng Yang, Wei Li, Bin Zhu, Wenqing Zhou, Huan Wang, Sumeng Li, Sihong Lu, Di Liu, Huadong Li, Adalbert Krawczyk, Mengji Lu, Dongliang Yang, Fei Deng, Ulf Dittmer, Mirko Trilling, Xin Zheng
Summary: The study quantified IgM and IgG antibodies recognizing SARS-CoV-2 in 349 symptomatic COVID-19 patients over 6 months, showing that IgM levels dropped after 3 months while IgG responses contracted but remained high at 6 months.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
Ning Jiang, Yan-Nan Liu, Jing Bao, Ran Li, Wen-Tao Ni, Xing-Yu Tan, Yu Xu, Li-Ping Peng, Xiao-Rong Wang, Yi-Ming Zeng, Dai-Shun Liu, Qing Xue, Jia-Shu Li, Ke Hu, Ya-Li Zheng, Zhan-Cheng Gao
Summary: This study found that patients aged ≥65 years, male, with comorbid diabetes, and presenting with cough and/or diarrhea upon admission were at a higher risk for severe COVID-19. Further stratification analysis showed that male patients with diabetes were more likely to develop severe COVID-19, highlighting the importance of close monitoring for these high-risk individuals.
CHINESE MEDICAL JOURNAL
(2021)
Article
Allergy
Marc Humbert, Arnaud Bourdin, Nikolaos G. Papadopoulos, Stephen T. Holgate, Nicola A. Hanania, David M. G. Halpin, Kenneth R. Chapman, Marcela Gavornikova, David B. Price, Alan Kaplan, Liam G. Heaney
Summary: Systemic corticosteroids are commonly used for treating asthma, but their prolonged or repeated use can result in significant adverse effects. Referring asthma patients who have received multiple courses of corticosteroids and still have uncontrolled symptoms to specialists for evaluation and treatment is crucial in improving patient outcomes.
Article
Allergy
Ioana Agache, Cezmi Akdis, Mubeccel Akdis, Giorgio Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Derek K. Chu, Stefano Del Giacco, Thomas Eiwegger, Breda Flood, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Irene Hernandez-Martin, Rebeca Knibb, Mika Makela, Parameswaran Nair, Liam O'Mahony, Nikolaos G. Papadopoulos, Alberto Papi, Hae-Sim Park, Luis Perez de Llano, Oliver Pfaar, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Oscar Palomares, Marek Jutel
Summary: Severe asthma poses significant challenges in management, but targeted treatments with biologicals offer new hope for patients. However, further research is needed on issues such as selection of biologicals, response definition, treatment duration, and cost-effectiveness.
Article
Critical Care Medicine
Nicola A. Hanania, David M. Mannino, Gerard J. Criner, Mark T. Dransfield, MeiLan K. Han, C. Elaine Jones, Sally Kilbride, David A. Lomas, Neil Martin, Fernando J. Martinez, Dave Singh, Robert A. Wise, David M. G. Halpin, Robson Lima, David A. Lipson
Summary: In the IMPACT trial, FF/UMEC/VI demonstrated superior efficacy compared to FF/VI and UMEC/VI in patients with symptomatic COPD and a history of exacerbations across all age groups, with a comparable safety profile.
Article
Critical Care Medicine
Abebaw M. Yohannes, Sheila Dryden, Richard Casaburi, Nicola A. Hanania
Summary: An effective 8-week PR program provides sustained improvement in anxiety and quality of life for COPD patients over a 2-year period, but short-term improvements in dyspnea, depression, and stress symptoms at 8 weeks were not maintained at 2 years.
Editorial Material
Respiratory System
Zuzana Diamant, Nicola A. Hanania
CURRENT OPINION IN PULMONARY MEDICINE
(2021)
Article
Critical Care Medicine
Laurie A. Lee, Zelie Bailes, Neil Barnes, Louis-Philippe Boulet, Dawn Edwards, Andrew Fowler, Nicola A. Hanania, Huib A. M. Kerstjens, Edward Kerwin, Robert Nathan, John Oppenheimer, Alberto Papi, Steven Pascoe, Guy Brusselle, Guy Peachey, Neal Sule, Maggie Tabberer, Ian D. Pavord
Summary: In patients with uncontrolled moderate or severe asthma using ICS/LABA, adding UMEC improved lung function but did not significantly reduce moderate and/or severe exacerbations. Single-inhaler FF/UMEC/VI is an effective treatment option with a favorable risk-benefit profile. Higher dose FF primarily reduced exacerbations, especially in patients with elevated biomarkers of type 2 airway inflammation. Further studies are needed to confirm the effects of type 2 inflammatory biomarkers on treatment outcomes in asthma.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Respiratory System
Abebaw M. Yohannes, Michelle N. Eakin, Janet T. Holbrook, Elizabeth A. Sugar, Robert Henderson, Anna M. Baker, Anne S. Casper, David A. Kaminsky, Alexis L. Rea, Anne M. Mathews, Loretta G. Que, Joe W. Ramsdell, Lynn B. Gerald, Robert A. Wise, Nicola A. Hanania
Summary: The study found that characteristics such as age, African-American race, sleep disturbance, and persistent phlegm are associated with mild cognitive impairment in patients with chronic obstructive pulmonary disease (COPD).
EXPERT REVIEW OF RESPIRATORY MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Tommi Tervonen, Fernando J. Martinez, Nicola A. Hanania, Sebastian Heidenreich, James M. Eudicone, Ileen Gilbert
Summary: The study reveals that patients prioritize attributes such as reduced exacerbations and faster onset of action in different treatment classes. Patients with asthma prefer budesonide/formoterol fumarate dihydrate (80/4.5 μg) pMDI, while those with COPD favor budesonide/formoterol fumarate dihydrate (160/4.5 μg) pMDI.
RESPIRATORY MEDICINE
(2021)
Review
Allergy
Amber N. Pepper, Nicola A. Hanania, Marc Humbert, Thomas B. Casale
Summary: Five biologic medications approved for treating uncontrolled asthma target elevated type 2 inflammatory markers like eosinophils, nitric oxide, or IgE. Factors such as asthma severity, biomarkers, and treatment goals should guide initial biologic choice, with shared decision-making with patients to optimize adherence. Monitoring response and troubleshooting are essential for patients with suboptimal responses, with potential need for changing biologic therapy or exploring other treatment options.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Immunology
Afshin Ebrahimpour, Min Wang, Li Li, Anil G. Jegga, Mark D. Bonnen, N. Tony Eissa, Ganesh Raghu, Soma Jyothula, Farrah Kheradmand, Nicola A. Hanania, Ivan O. Rosas, Yohannes T. Ghebre
Summary: This study suggests that PPIs, such as esomeprazole, may have an antifibrotic role in IPF by directly regulating the MAPK/Nrf2/HO1 pathway to influence the disease process favorably. The research found that esomeprazole controls pro-inflammatory and profibrotic molecules through Nrf2 nuclear translocation and induction of HO1, with additional involvement of the MAPK pathway. High throughput RNA-seq analysis supported the antifibrotic effect of esomeprazole and revealed novel potential targets for IPF treatment.
JOURNAL OF INFLAMMATION-LONDON
(2021)
Article
Respiratory System
Nicola A. Hanania, Abebaw M. Yohannes, Ayca Ozol-Godfrey, Michael Tocco, Thomas Goodin, Sanjay Sharma, Shahin Sanjar
Summary: In patients with moderate-to-very-severe COPD, those with comorbid anxiety and depression (A/D) showed improvements in FEV1 and SGRQ scores following treatment with nebulized glycopyrrolate (GLY) 25 μg. Regardless of baseline A/D status, GLY demonstrated significant improvements in symptoms.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
(2021)
Article
Respiratory System
Arnaud Bourdin, Gerard Criner, Gilles Devouassoux, Mark Dransfield, David M. G. Halpin, MeiLan K. Han, C. Elaine Jones, Ravi Kalhan, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Jose M. Echave-Sustaeta Maria-Tome, Neil Martin, Fernando J. Martinez, Holly Quasny, Lynda Sail, Thomas M. Siler, Dave Singh, Byron Thomashow, Henrik Watz, Robert Wise, Nicola A. Hanania
Summary: The IMPACT trial demonstrated that FF/UMEC/VI reduced moderate/severe exacerbation rates and risks, and improved lung function in both Western Europe and North America. However, differences were observed between the regions in terms of SGRQ total score and pneumonia incidence.
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION
(2021)
Meeting Abstract
Allergy
Zachary Schwartz, Carolyn Skowronski, Anne Roc, Bradley Chipps, Nicola Hanania, Linda Rogers, Eileen Wang, Michael Wechsler
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Meeting Abstract
Allergy
Nicola Hanania, Zelie Bailes, Sarah Chang, Andrew Fowler, Robson Lima, David Mannino, Mark Millard, Joseph Spahn, Steve Weinstein, Robert Nathan
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)